Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma

doi:10.4254/wjh.v17.i11.112364

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

(43)

(44)

(0)

(9)

(596)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Nov 27, 2025; 17(11): 112364
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112364

Full Size Figure Download Figure

Figure 3 Correlation analysis. A: Correlation between upregulated genes in the response group and immune cell infiltration scores; B: Correlation between upregulated genes in the non-response group and immune cell infiltration scores; C-E: Kaplan-Meier curves for natural killer T cells (C), T helper 1 cells (D), and CD4+ central memory T cells (E), respectively, comparing high and low expression levels in the study population. NKT: Natural killer T cells; Th1: T helper 1 cells; CD4+ Tcm: CD4+ central memory T cells.

Citation: Wang LJ, Cui Y, Huang LF, Zhang JQ, Zhao TT, Wang HW, Liu M, Jin KM, Wang K, Xing BC. Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma. World J Hepatol 2025; 17(11): 112364
URL: https://www.wjgnet.com/1948-5182/full/v17/i11/112364.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i11.112364

Wang LJ, Cui Y, Huang LF, Zhang JQ, Zhao TT, Wang HW, Liu M, Jin KM, Wang K, Xing BC. Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma. World J Hepatol 2025; 17(11): 112364 [PMID: 41368112 DOI: 10.4254/wjh.v17.i11.112364]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.